Table 1.
Baseline characteristics
| Children with at least 1 fundus/OCT/VF/ERG assessment AFTER initiating vigabatrin | No.a |
|---|---|
|
| |
| Sex | |
| Female | 145/284 (51.1) |
| Indication for vigabatrin | |
| Seizures—systemic/genetic abnormalities | 111 (39.1) |
| Tuberous sclerosis | 49 (17.3) |
| Infantile spasms (not otherwise specified) | 77 (27.1) |
| Seizures—structural brain abnormalities | 39 (13.7) |
| Lennox-Gastaut syndrome | 26 (9.2) |
| Hypoxic/perinatal brain injury | 16 (5.6) |
| Epilepsy (not otherwise specified) | 12 (4.2) |
| Other | 3(1.1) |
| Age at initiation, years | |
| Mean ± SD | 2.09 ± 2.9 |
| Median (Q1, Q3) | 1.0 (0.6, 2.1) |
| Range | 0.1 to 16.0 |
| Duration of treatment, months | |
| Mean ± SD | 28.8 ± 33.0 |
| Median (Q1, Q3) | 14.8 (7.1,41.4) |
| Range | 0.2 to 139.4 |
| Time until first eye assessment (months) | |
| Mean ± SD | 4.62 ± 7.54 |
| Median (Q1, Q3) | 2.07 (0.7, 4.7) |
| Range | 0.00 to 58.0 |
| First assessment exclusively for vigabatrin | 154 (54.2) |
ERG, electroretinogram; OCT, optical coherence tomography; Q1, first quartile; Q3, third quartile; SD, standard deviation; VF, visual field.
a
Parenthetical values indicate percentage, except as noted.